

Dossier portfolio

October 2016

SPECIALITIES

ONCOLOGY & INHALATION	FORM	DOSAGE STRENGTHS	DOSSIER
IMATINIB	TABS	100MG, 400 MG	YES
ANASTROZOL	TABS	1 MG	YES
LETRIZOL	TABS	2,5 MG	YES
TIOTROPIUM BROMIDE	CAPS	18MCG	UNDER DEVELOPMENT

OTHER GENERICS

ANTI INFECTIVES	FORM	DOSAGE STRENGTHS	DOSSIER
MOXIFLOXACIN	TABS	400MG	YES

CARDIOVASCULAR	FORM	DOSAGE STRENGTHS	DOSSIER
EZETIMIBE	TABS	10MG	YES
ROSUVASTATINE	TABS	5MG, 10MG, 20MG	YES
OLMESARTAN MEDOXOMIL	TABS	10MG, 20MG, 40MG	YES
OLMESARTAN MEDOXOMIL + HCTZ	TABS	20/12,5MG, 20/25MG, 40/12,5MG, 40/25MG	YES
IVABRADINE	TABS	5 MG, 7,5 MG	YES
AMLODIPINE + OLMESARTAN	TABS	10/40MG, 5/20MG, 5/40MG	YES
AMLODIPINE + OLMESARTAN + HCTZ	TABS	5MG/12.5MG/20MG, 5MG/12.5MG/40MG, 5MG/25MG/40MG, 10MG/12.5MG/40MG, 10MG/25MG/40MG	UNDER DEVELOPMENT
AMLODIPINE + VALSARTAN + HCTZ	TABS	5MG/160MG/12.5MG, 10MG/160MG/12.5MG, 5MG/160MG/25MG, 10MG/320MG/25MG	YES
DIOSMINE	TABS	500 MG	UNDER DEVELOPMENT
PITAVASTATIN	TABS	1MG, 2 MG, 4 MG	UNDER DEVELOPMENT
METFORMIN + VILDAGLIPTIN	TABS	1 G/50MG, 850 MG/50MG	UNDER DEVELOPMENT
METFORMIN + SITAGLIPTIN	TABS	1 G/50MG, 850 MG/50MG	UNDER DEVELOPMENT
VILDAGLIPTIN	TABS	50 MG	UNDER DEVELOPMENT
RIVAROXABAN	TABS	10 MG/15MG/20MG	UNDER DEVELOPMENT
PRAVASTATIN/FENOFIBRATE	CAPS	40MG/160MG	UNDER DEVELOPMENT

CENTRAL NERVOUS SYSTEM	FORM	DOSAGE STRENGTHS	DOSSIER
PREGABALIN	TABS	25MG, 75MG, 150MG, 300MG	YES
RASAGILINE	TABS	1MG	YES
ARIPIPRAZOL	TABS	5MG, 10MG, 15MG, 30MG	YES
ESLICARBAZEPIN	TABS	800 MG	UNDER DEVELOPMENT

GENITO-URINARY SYSTEM	FORM	DOSAGE STRENGTHS	DOSSIER
SOLIFENACIN	TABS	5MG, 10MG	UNDER DEVELOPMENT
TADALAFIL	TABS	5MG, 10MG, 20MG	YES
VARDENAFIL	TABS	5MG, 10MG, 20MG	YES
VARDENAFIL	ODT TABS	10MG	YES
SILODOSIN	CAPS	4MG, 8MG	UNDER DEVELOPMENT

MUSCULOSKELETAL	FORM	DOSAGE STRENGTHS	DOSSIER
ETORICOXIB	TABS	30MG, 60MG, 90MG, 120 MG	YES
CELECOXIB	CAPS	100MG, 200MG	YES
ALENDRONIC ACID + VITAMIN D	TABS	70MG/140MCG	YES

RESPIRATORY SYSTEM	FORM	DOSAGE STRENGTHS	DOSSIER
ROFLUMILAST	TABS	500MCG	YES
DESLORATADINE	ODT TABS	5 MG	YES

STRICTLY CONFIDENTIAL

Patent information: Availability of products is subject to patent restriction in countries where applicable patents are in effect. Products protected by valid patents are being developed within the scope of activities foreseen in Art. 10.6 of the Directive 2001/83 and Art. 52.1, b) of the Spanish Patent Act i.e. activities carried out to obtain a Marketing Authorisation in Spain or out of Spain.

cinfa@cinfa.com